Literature DB >> 8545123

Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis.

P Esteve1, L del Peso, J C Lacal.   

Abstract

We have previously reported that rho genes, members of the ras superfamily, are tumorigenic when overexpressed in NIH 3T3 cells. As other known oncogenes, they also induce apoptosis after serum deprivation but not in the presence of growth factors. In the present study, we provide evidence that overexpression of the Aplysia Rho protein in NIH 3T3 cells induces the generation of phosphatidylcholine (PC)-derived second messengers as a result of activation of a PC-specific phospholipase D (PC-PLD) as previously reported for ras-transformed cells. In contrast, removal of serum in the Rho transfectants, but not in normal NIH 3T3 cells or cells transformed by the ras oncogene, induced the production of ceramides as a result of activation of an sphingomyelinase (SMase). Furthermore, the rho-expressing cells underwent apoptosis in the presence of serum when exogenous ceramides were added, and this process was accelerated if cells were treated with exogenous SMase. Thus, Rho proteins act as an initiation signal that is necessary but not sufficient for the induction of apoptosis in NIH 3T3 cells. We propose here that induction of apoptosis in NIH 3T3 cells requires two complementary signals: an initiation signal generated even in the presence of serum which 'primes' the cells, making them sensitive to a progression signal, triggered by serum removal, which we have identified as generation of ceramides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545123

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities.

Authors:  F M Donovan; C J Pike; C W Cotman; D D Cunningham
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

2.  Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells.

Authors:  Guillaume Sarrabayrouse; Cindy Synaeve; Kevin Leveque; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

3.  Suppressor gene analysis reveals an essential role for sphingolipids in transport of glycosylphosphatidylinositol-anchored proteins in Saccharomyces cerevisiae.

Authors:  M Skrzypek; R L Lester; R C Dickson
Journal:  J Bacteriol       Date:  1997-03       Impact factor: 3.490

4.  Characterization of RhoA-mediated chemoresistance in gastric cancer cells.

Authors:  Won Ki Kang; Inkyoung Lee; Chaehwa Park
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

5.  RhoG GTPase controls a pathway that independently activates Rac1 and Cdc42Hs.

Authors:  C Gauthier-Rouvière; E Vignal; M Mériane; P Roux; P Montcourier; P Fort
Journal:  Mol Biol Cell       Date:  1998-06       Impact factor: 4.138

6.  Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production.

Authors:  N Embade; P F Valerón; S Aznar; E López-Collazo; J C Lacal
Journal:  Mol Biol Cell       Date:  2000-12       Impact factor: 4.138

7.  Cytoplasmic death signal triggered by SRC-mediated phosphorylation of the adenovirus E4orf4 protein.

Authors:  Marie-Claude Gingras; Claudia Champagne; Mélanie Roy; Josée N Lavoie
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

8.  Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion.

Authors:  A E Bielawska; J P Shapiro; L Jiang; H S Melkonyan; C Piot; C L Wolfe; L D Tomei; Y A Hannun; S R Umansky
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

9.  The role of FilGAP-filamin A interactions in mechanoprotection.

Authors:  Yulia Shifrin; Pamela D Arora; Yasutaka Ohta; David A Calderwood; Christopher A McCulloch
Journal:  Mol Biol Cell       Date:  2009-01-14       Impact factor: 4.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.